February 22, 2017 5:39pm

 

What are investors waiting for, Godot? Trading has even taken the bench away!

While management teams’ stay on the sidelines with impunity which I call in some cases fiduciary negligence

Leaving investor’s portfolios to shrivel ...

 

I am tracking the numbers and taking “names” … so investors can be more aware!

 

What happened, what did it all mean and why was it important in today’s sector outcomes

 

I answer one question, short and without sweeteners; in which company should investors put, keep and commit their money

 

 

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds, and just because a stock underperforms the market doesn’t mean you have to lose money.

 

 

U.S. equities closed mixed Wednesday after minutes from the Federal Reserve's previous meeting hinted that a rate hike is coming "fairly soon."

The NASDAQ closed DOWN -5.32 or -0.09% to 5860.63 and the DOW closed UP +32.60 or +0.16% to 20,775.60.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was negative with an A/DL of 10/27 and 6 flats;
  • The mid-day stayed negative with an A/DL of 16/24 and 3 flats;
  • The close continued negative with an A/DL of 14/27 and 2 flat;

 

 

Henry’omics:

From the pre-open’s investor’s letter title, “what will make our sector investible? We need to drain the swamp of those who have sold investors the line; we’re here to facilitate cures that gave only dilution, greater losses and false hope.”

  • Reiterating, “Strike a blow for investor rights by those who have hyped while maintaining huge salaries and spending with questionable advances”

“The iShares Nasdaq Biotech ETF (IBB) and the SPDR S&P Biotech ETF (XBI) both logged four consecutive weeks of gains. They have not posted such streaks since August 2016 and June 2016, respectively, at a time when biotech stocks were on a roller coaster, mired in political rhetoric in the heat of the campaign season.”

  • Lately, when traders have glanced at their terminals, they’ve been greeted by a sea of red.

Nearly everywhere, markets are in rally mode, while “our” universe has dropped to yet another down close. Cell therapy stocks are just NOT holding their own.

 

What has happened to the cell therapy sector … stuck at the dump, they must unload the excess freight of management mismatches, miscues and missteps!

What are we back to – selling into any strength and any financial results?

Best move: trade selectively … this sector is paused by pessimism, followed by growing sceptics and flagellating with complacency!

 

 

Indexes, the ebb and flow:

The iShares Russell 2000 (IWM) indicated a negative -0.43% in the pre- open and closed DOWN -0.44%

The iShares NASDAQ Biotechnology (IBB) indicated a negative -0.30% in the pre-open and closed DOWN -0.85%

 

 

Pre-open indication tally, 2 hit (BSTG and BLUE) and 3 miss (ONVO, ONCE and VSTM:

  • Biostage (BSTG) closed DOWN -$0.022 – hit, deserved and more;
  • bluebird bio (BLUE) closed down -$2.25 – hit, always with financial results;
  • Organovo holdings (ONVO) closed DOWN -$0.03 – miss, I am still all in;
  • Spark Therapeutics (ONCE) closed DOWN -$3.33 – miss, oversold;
  • Verastem (VSTM) closed DOWN -$0.04 – miss, with $2.35 in cash per share?

 

 

The downside shows a pricing trend of:

  • Wednesday’s decliners ranged from -0.00% <KOOL> to -6.81% <OSIR> in 27 equities;
  • Tuesday’s decliners ranged from -0.17% <JUNO> to -5.63% <FCSC> in 21 equities;
  • Monday, the market was closed;
  • Friday’s decliners ranged from -0.12% <ONCE> to -7.06% <NWBO> in 17 equities;
  • Thursday’s decliners ranged from -0.34% <XON> to -6.44% <IMUC> in 26 equities;
  • Last Wednesday’s decliners ranged from -0.06% <BLUE> to -6.54% <ISCO> in 14 equities;

 

The upside shows a pricing trend of:

  • Wednesday’s gainers ranged from +0.39% <CLBS> to +14.47% <BCLI> in 14 equities;
  • Tuesday’s gainers ranged from +0.34% <ONCE> to +11.94% <BSTG> in 17 equities;
  • Monday, the market was closed;
  • Friday’s gainers ranged from +0.24% <MDXG> to +15.93% <FATE> in 24 equities;
  • Thursday’s gainers ranged from +0.32% <CAPR> to +18.55% <CUR> in 16 equities;
  • Last Wednesday’s gainers ranged from +0.31% <FATE> to +6.32% <JUNO> in 25 equities;

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Wednesday traded near 11.8;

·         Tuesday traded near 11.8;

·         Monday was a holiday;

·         Friday traded near 11.5;

·         Thursday traded near 11.7;

·         Last Wednesday traded near 11.6 – 8% higher;

                                                                                                                                                                               

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.